Amgen Inc. $AMGN Shares Bought by Hilltop Holdings Inc.

Hilltop Holdings Inc. grew its stake in Amgen Inc. (NASDAQ:AMGN) by 77.2% in the 1st quarter, according to its most recent filing with the SEC. The firm owned 6,089 shares of the medical research company’s stock after buying an additional 2,653 shares during the quarter. Hilltop Holdings Inc.’s holdings in Amgen were worth $2,142,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also made changes to their positions in AMGN. High Note Wealth LLC raised its holdings in Amgen by 5.8% in the fourth quarter. High Note Wealth LLC now owns 508 shares of the medical research company’s stock valued at $166,000 after acquiring an additional 28 shares in the last quarter. TAGStone Capital Inc. lifted its stake in Amgen by 0.7% in the fourth quarter. TAGStone Capital Inc. now owns 4,129 shares of the medical research company’s stock worth $1,351,000 after acquiring an additional 28 shares during the last quarter. Verus Capital Partners LLC grew its holdings in Amgen by 2.3% during the 4th quarter. Verus Capital Partners LLC now owns 1,231 shares of the medical research company’s stock worth $403,000 after acquiring an additional 28 shares in the last quarter. Destination Wealth Management grew its holdings in Amgen by 2.1% during the 4th quarter. Destination Wealth Management now owns 1,393 shares of the medical research company’s stock worth $456,000 after acquiring an additional 29 shares in the last quarter. Finally, Breakwater Capital Group increased its position in shares of Amgen by 1.4% in the 1st quarter. Breakwater Capital Group now owns 2,039 shares of the medical research company’s stock valued at $717,000 after purchasing an additional 29 shares during the last quarter. 76.50% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at Amgen

In other Amgen news, SVP Nancy A. Grygiel sold 1,237 shares of the company’s stock in a transaction on Monday, May 4th. The shares were sold at an average price of $323.73, for a total value of $400,454.01. Following the completion of the transaction, the senior vice president owned 7,009 shares in the company, valued at $2,269,023.57. This represents a 15.00% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. 0.85% of the stock is owned by corporate insiders.

Amgen Stock Up 1.2%

Shares of NASDAQ:AMGN opened at $376.04 on Friday. The company has a market capitalization of $202.95 billion, a PE ratio of 26.17, a P/E/G ratio of 3.76 and a beta of 0.41. The company has a current ratio of 1.26, a quick ratio of 1.01 and a debt-to-equity ratio of 5.65. Amgen Inc. has a twelve month low of $269.77 and a twelve month high of $391.29. The firm has a 50 day simple moving average of $351.28 and a 200-day simple moving average of $351.80.

Amgen (NASDAQ:AMGN) last issued its earnings results on Thursday, April 30th. The medical research company reported $5.15 earnings per share (EPS) for the quarter, beating the consensus estimate of $4.77 by $0.38. The business had revenue of $8.62 billion during the quarter, compared to analysts’ expectations of $8.58 billion. Amgen had a net margin of 20.96% and a return on equity of 137.41%. The company’s revenue for the quarter was up 5.8% on a year-over-year basis. During the same quarter in the prior year, the business posted $4.90 EPS. Amgen has set its FY 2026 guidance at 21.700-23.100 EPS. On average, equities analysts predict that Amgen Inc. will post 22.31 EPS for the current fiscal year.

Analyst Ratings Changes

AMGN has been the topic of a number of analyst reports. Wall Street Zen lowered shares of Amgen from a “buy” rating to a “hold” rating in a report on Saturday, June 27th. Cantor Fitzgerald reiterated a “neutral” rating and set a $350.00 target price on shares of Amgen in a research note on Monday, July 6th. BMO Capital Markets reissued an “outperform” rating and issued a $400.00 target price on shares of Amgen in a report on Wednesday, July 1st. Morgan Stanley cut their price target on Amgen from $340.00 to $333.00 and set an “equal weight” rating on the stock in a research note on Wednesday, July 8th. Finally, Royal Bank Of Canada reaffirmed a “positive” rating on shares of Amgen in a report on Thursday, June 18th. Two investment analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating, fifteen have issued a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat.com, Amgen presently has an average rating of “Hold” and an average price target of $356.62.

About Amgen

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.